Bertoni Alain G, Bonds Denise E, Chen Haiying, Hogan Patricia, Crago Lenore, Rosenberger Erica, Barham Ann Hiott, Clinch C Randall, Goff David C
Division of Public Health Sciences, Department of Epidemiology and Prevention, Wake Forest University Baptist Medical Center, Medical Center Blvd, Winston-Salem, NC 27157, USA.
Arch Intern Med. 2009 Apr 13;169(7):678-86. doi: 10.1001/archinternmed.2009.44.
Physician adherence to National Cholesterol Education Program clinical practice guidelines has been poor.
We recruited 68 primary care family and internal medicine practices; 66 were randomly allocated to a study arm; 5 practices withdrew, resulting in 29 receiving the Third Adult Treatment Panel (ATP III) intervention and 32 receiving an alternative intervention focused on the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7). The ATP III providers received a personal digital assistant providing the Framingham risk scores and ATP III-recommended treatment. All practices received copies of each clinical practice guideline, an introductory lecture, 1 performance feedback report, and 4 visits for intervention-specific academic detailing. Data were abstracted at 61 practices from random samples of medical records of patients treated from June 1, 2001, through May 31, 2003 (baseline), and from May 1, 2004, through April 30, 2006 (follow-up). The proportion screened with subsequent appropriate decision making (primary outcome) was calculated. Generalized estimating equations were used to compare results by arm, accounting for clustering of patients within practices.
We examined 5057 baseline and 3821 follow-up medical records. The screening rate for lipid levels increased from 43.6% to 49.0% (ATP III practices) and from 40.1% to 50.8% (control practices) (net difference, -5.3% [P = .22]). Appropriate management of lipid levels decreased slightly (73.4% to 72.3%) in ATP III practices and more markedly (79.7% to 68.9%) in control practices. The net change in appropriate management favored the intervention (+9.7%; 95% confidence interval [CI], 2.8%-16.6% [P < .01]). Appropriate drug prescription within 4 months decreased in both arms (38.8% to 24.8% in ATP III practices and 45.3% to 24.1% in control practices; net change, +7.2% [P = .37]) Overtreatment declined from 6.6% to 3.9% in ATP III and rose from 4.2% to 6.4% in control practices (net change, -4.9% [P = .01]).
A multifactor intervention including personal digital assistant-based decision support may improve primary care physician adherence to the ATP III guidelines. Trial Registration clinicaltrials.gov Identifier: NCT00224848.
医生对国家胆固醇教育计划临床实践指南的依从性较差。
我们招募了68个初级保健家庭和内科诊所;66个被随机分配到一个研究组;5个诊所退出,最终29个接受第三次成人治疗小组(ATP III)干预,32个接受侧重于美国国家联合委员会关于高血压预防、检测、评估和治疗的第七次报告(JNC - 7)的替代干预。接受ATP III干预的提供者获得了一个提供弗明汉风险评分和ATP III推荐治疗方案的个人数字助理。所有诊所都收到了各临床实践指南的副本、一次 introductory lecture(此处原文可能有误,推测为“入门讲座”)、一份绩效反馈报告以及4次针对特定干预的学术详细讲解。在61个诊所中,从2001年6月1日至2003年5月31日(基线期)以及2004年5月1日至2006年4月30日(随访期)治疗的患者的随机医疗记录样本中提取数据。计算经过后续适当决策筛选的比例(主要结果)。使用广义估计方程按组比较结果,同时考虑诊所内患者的聚类情况。
我们检查了5057份基线医疗记录和3821份随访医疗记录。ATP III干预组的血脂水平筛查率从43.6%提高到49.0%,对照组从40.1%提高到50.8%(净差异为 -5.3% [P = 0.22])。ATP III干预组血脂水平的适当管理略有下降(从73.4%降至72.3%),而对照组下降更为明显(从79.7%降至68.9%)。适当管理的净变化有利于干预组(+9.7%;95%置信区间[CI],2.8% - 16.6% [P < 0.01])。两组在4个月内适当药物处方率均下降(ATP III干预组从38.8%降至24.8%,对照组从45.3%降至24.1%;净变化为 +7.2% [P = 0.37])。ATP III干预组过度治疗率从6.6%降至3.9%,对照组从4.2%升至6.4%(净变化为 -4.9% [P = 0.01])。
包括基于个人数字助理的决策支持在内的多因素干预可能会提高初级保健医生对ATP III指南的依从性。试验注册 clinicaltrials.gov标识符:NCT00224848。